Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
12
×
life sciences
national blog main
12
×
boston blog main
boston top stories
national top stories
deals
san francisco blog main
san francisco top stories
boston
gene editing
national
clinical trials
crispr
editas medicine
gene therapy
new york blog main
new york top stories
novartis
roche
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer
celgene
detroit blog main
detroit top stories
indiana blog main
indiana top stories
pfizer
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alexion pharmaceuticals
What
gene
12
×
therapy
medicine
editing
therapeutics
bio
crispr
drug
editas
roundup
advanced
approval
disease
experimental
fda
humans
medicines
research
roche
treatment
trial
abbvie
access
allergan
alliance
alnylam’s
alzheimer’s
beam
becker
benefit
betting
bff
billion
billions
biopharma
biotech
blessing
bosley
capacity
car
Language
unset
Current search:
biotech
×
" national blog main "
×
gene
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M